Do analysts rate ZYBT or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, ZYBT or BFRI?

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 5.13 -$9.98M N/A N/A Biofrontera $41.71M 0.37 -$10.54M -$0.97 N/A

Does the media favor ZYBT or BFRI?

In the previous week, Zhengye Biotechnology had 3 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat Zhengye Biotechnology's score of 0.29 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 555.74%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to BFRI or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat Dogwood Therapeutics' score of 0.37 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BFRI or RYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BFRI or RYM?

Biofrontera has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.37 -$10.54M -$0.97 N/A RYTHM $17.28M 2.82 -$33.26M -$10.53 N/A

Is BFRI or RYM more profitable?

RYTHM has a net margin of -6.20% compared to Biofrontera's net margin of -25.66%. RYTHM's return on equity of -12.57% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -25.66% -515.34% -53.91% RYTHM -6.20% -12.57% -2.60%

Does the media prefer BFRI or RYM?

In the previous week, RYTHM had 2 more articles in the media than Biofrontera. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat RYTHM's score of 0.75 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RYTHM 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BFRI or SCLX?

Biofrontera has higher revenue and earnings than Scilex. Biofrontera is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.37 -$10.54M -$0.97 N/A Scilex $30.25M 1.88 -$358.73M -$40.47 N/A

Is BFRI or SCLX more profitable?

Biofrontera has a net margin of -25.66% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -25.66% -515.34% -53.91% Scilex -1,110.17% N/A -143.55%

Do analysts prefer SCYX or BFRI?

SCYNEXIS presently has a consensus price target of $24.00, suggesting a potential upside of 365.12%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities research analysts clearly believe SCYNEXIS is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCYX or BFRI more profitable?

Biofrontera has a net margin of -25.66% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -57.16% -39.48% Biofrontera -25.66% -515.34% -53.91%

Does the media prefer SCYX or BFRI?

In the previous week, SCYNEXIS had 5 more articles in the media than Biofrontera. MarketBeat recorded 7 mentions for SCYNEXIS and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat SCYNEXIS's score of 0.72 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biofrontera (BFRI) Competitors

$1.21 -0.06 (-4.72%)

As of 04:00 PM Eastern

Compare

BFRI vs. ZYBT, DWTX, RYM, SCLX, and SCYX

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include Zhengye Biotechnology (ZYBT), Dogwood Therapeutics (DWTX), RYTHM (RYM), Scilex (SCLX), and SCYNEXIS (SCYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology has a beta of -2.74, meaning that its stock price is 374% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Zhengye Biotechnology had 3 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat Zhengye Biotechnology's score of 0.29 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zhengye Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Zhengye Biotechnology's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Biofrontera	-25.66%	-515.34%	-53.91%

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	5.13	-$9.98M	N/A	N/A
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A

Summary

Biofrontera beats Zhengye Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Dogwood Therapeutics?

Biofrontera (NASDAQ:BFRI) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat Dogwood Therapeutics' score of 0.37 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dogwood Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Dogwood Therapeutics' return on equity of -108.57% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Biofrontera has higher revenue and earnings than Dogwood Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 555.74%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Summary

Dogwood Therapeutics beats Biofrontera on 7 of the 13 factors compared between the two stocks.

How does Biofrontera compare to RYTHM?

Biofrontera (NASDAQ:BFRI) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 3.5% of RYTHM shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biofrontera has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, RYTHM has a beta of 9.47, meaning that its share price is 847% more volatile than the broader market.

In the previous week, RYTHM had 2 more articles in the media than Biofrontera. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat RYTHM's score of 0.75 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RYTHM	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biofrontera has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A
RYTHM	$17.28M	2.82	-$33.26M	-$10.53	N/A

RYTHM has a net margin of -6.20% compared to Biofrontera's net margin of -25.66%. RYTHM's return on equity of -12.57% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
RYTHM	-6.20%	-12.57%	-2.60%

Summary

Biofrontera beats RYTHM on 9 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Scilex?

Biofrontera (NASDAQ:BFRI) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biofrontera had 2 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Scilex. Biofrontera's average media sentiment score of 1.00 beat Scilex's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Scilex	Neutral

Biofrontera has higher revenue and earnings than Scilex. Biofrontera is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A
Scilex	$30.25M	1.88	-$358.73M	-$40.47	N/A

Biofrontera has a net margin of -25.66% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Scilex	-1,110.17%	N/A	-143.55%

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biofrontera has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Scilex has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

Summary

Biofrontera beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Biofrontera compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, SCYNEXIS had 5 more articles in the media than Biofrontera. MarketBeat recorded 7 mentions for SCYNEXIS and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.00 beat SCYNEXIS's score of 0.72 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biofrontera has a net margin of -25.66% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Biofrontera	-25.66%	-515.34%	-53.91%

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SCYNEXIS has higher earnings, but lower revenue than Biofrontera. SCYNEXIS is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.49	-$8.61M	-$3.84	N/A
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A

SCYNEXIS has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

SCYNEXIS presently has a consensus price target of $24.00, suggesting a potential upside of 365.12%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities research analysts clearly believe SCYNEXIS is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SCYNEXIS beats Biofrontera on 10 of the 16 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.26M	$11.84B	$7.02B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-1.25	788.51	269.19	24.72
Price / Sales	0.37	740.84	588.76	97.77
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	1.34	10.33	11.27	6.42
Net Income	-$10.54M	$2.77B	$3.45B	$347.03M
7 Day Performance	1.68%	2.04%	3.56%	2.49%
1 Month Performance	10.00%	-1.57%	-0.58%	-1.04%
1 Year Performance	27.84%	191.33%	77.52%	23.22%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.4322 of 5 stars	$1.21 -4.7%	N/A	+34.2%	$16.26M	$41.71M	N/A	70	Positive News Upcoming Earnings
ZYBT Zhengye Biotechnology	0.5945 of 5 stars	$2.36 +84.4%	N/A	-63.7%	$60.66M	$16.64M	N/A	278	Gap Down High Trading Volume
DWTX Dogwood Therapeutics	2.9594 of 5 stars	$1.83 +2.2%	$12.00 +555.7%	-62.6%	$60.20M	N/A	N/A	5	Upcoming Earnings
RYM RYTHM	1.1133 of 5 stars	$24.99 -1.8%	N/A	N/A	$55.44M	$17.28M	N/A	140	Earnings Report Gap Up
SCLX Scilex	0.2662 of 5 stars	$6.52 +0.8%	N/A	-55.8%	$54.94M	$30.25M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. ZYBT, DWTX, RYM, SCLX, and SCYX

How does Biofrontera compare to Zhengye Biotechnology?

Summary

How does Biofrontera compare to Dogwood Therapeutics?

Summary

How does Biofrontera compare to RYTHM?

Summary

How does Biofrontera compare to Scilex?

Summary

How does Biofrontera compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. ZYBT, DWTX, RYM, SCLX, and SCYX

How does Biofrontera compare to Zhengye Biotechnology?

Do analysts rate ZYBT or BFRI?

Do institutionals & insiders believe in ZYBT or BFRI?

Which has more volatility and risk, ZYBT or BFRI?

Does the media favor ZYBT or BFRI?

Is ZYBT or BFRI more profitable?

Which has better valuation & earnings, ZYBT or BFRI?

Summary

How does Biofrontera compare to Dogwood Therapeutics?

Does the media refer more to BFRI or DWTX?

Do insiders and institutionals have more ownership in BFRI or DWTX?

Is BFRI or DWTX more profitable?

Which has preferable valuation & earnings, BFRI or DWTX?

Do analysts rate BFRI or DWTX?

Which has more volatility & risk, BFRI or DWTX?

Summary

How does Biofrontera compare to RYTHM?

Do insiders & institutionals believe in BFRI or RYM?

Which has more volatility & risk, BFRI or RYM?

Does the media prefer BFRI or RYM?

Do analysts prefer BFRI or RYM?

Which has higher valuation and earnings, BFRI or RYM?

Is BFRI or RYM more profitable?

Summary

How does Biofrontera compare to Scilex?

Do analysts rate BFRI or SCLX?

Does the media refer more to BFRI or SCLX?

Which has higher valuation & earnings, BFRI or SCLX?

Is BFRI or SCLX more profitable?

Do insiders and institutionals believe in BFRI or SCLX?

Which has more risk & volatility, BFRI or SCLX?

Summary

How does Biofrontera compare to SCYNEXIS?

Does the media prefer SCYX or BFRI?

Is SCYX or BFRI more profitable?

Do insiders & institutionals hold more shares of SCYX or BFRI?

Which has stronger earnings & valuation, SCYX or BFRI?

Which has more risk & volatility, SCYX or BFRI?

Do analysts prefer SCYX or BFRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools